4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics, Inc.

4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations.

We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: 
-	Dare to Cure
-	Break Boundaries 
-	Beyond Yourself 
-	Prepare & Executive Relentlessly 

Join us in creating the future of genetic medicine.

Pappas Capital

Perceptive Advisors

Pfizer Venture Investments

QUAD Investment Management

Viking Global Investors

Longevity Vision Fund

MiraeAsset Financial Group

Berkeley Catalyst Fund (BCF)

Biotechnology Value Fund

BVF Partners

Chiesi Ventures

4D Molecular Therapeutics

4DMT is excited to be featured on BioSpace’s 2024 #BestPlacesToWork small employer list — a list of the top ranked life science employers in North America based on industry vote. Thank you, BioSpace for this honorable recognition, and our 4DMT family for making this award possible. Interested in joining our team? Learn more here: https://lnkd.in/ge8w9xnt

Thank you, Emily's Entourage! We are immensely honored to be a Dream Team Sponsor for the 2023 Scientific Symposium taking place next month. It's a privilege to stand alongside organizations like EE and work together to accelerate treatments for the final 10% of individuals with #cysticfibrosis. We are grateful for the passionate support from EE and the entire cystic fibrosis community.

We are gratified to receive additional financial and research support from the CF Foundation for our cutting edge, next-generation lung gene delivery technology!

This month, our #4DMT team will be participating in a fireside chat at the 6th Annual Evercore ISI #HealthCONx Conference. We look forward to connecting! Register for the webcast here: https://lnkd.in/e-uZM_6S
#investorconference

Last week, the 4DMT team participated at #NACFC 2023, where we shared positive data from our Phase 1/2 AEROW clinical trial of 4D-710. We are grateful for the opportunity to connect with the cystic fibrosis community and help advance new treatments for CF.

Today, we announced our third quarter financial results and operational highlights, including updates across our ophthalmology, pulmonology, and cardiology programs. Read more about our recent progress and anticipated upcoming milestones: https://lnkd.in/gpUQkv5w  #earnings

Our team was thrilled to be on-site in San Francisco this past weekend for #AAO23 to hear from colleagues and exhibitors on the latest technologies and treatments in ophthalmology.

We are thrilled to present positive interim data from Phase 1/2 AEROW clinical trial of aerosolized 4D-710 at Cystic Fibrosis Foundation’s North American Cystic Fibrosis Conference this week in Phoenix, Arizona. 
 
We also would like to warmly welcome Alan H. Cohen, MD, who has joined 4DMT as SVP, Therapeutic Area Head of Pulmonology. 
 
Finally, we are gratified to announce that the Cystic Fibrosis Foundation has increased their funding commitment under our research agreement by $2.8 million to a total of $6.3 million. The increased financial commitment brings their total historical commitment to the 4DMT CF program to over $20 million.
 
Stop by kiosk #2 to connect with our team and learn more about the latest progress with 4D-710, an investigational genetic medicine for adults with #cysticfibrosis lung disease. Read the full release here: https://lnkd.in/dgKfuVwd 
 
Register for the webcast here: https://lnkd.in/g6ztcSZR

People with #CysticFibrosis who are not amenable or do not respond to CFTR modulators deserve treatments that address the underlying cause of the disease. We are on a mission to develop a potentially transformative new therapy to treat a broad range of people with #CF. Learn about 4D-710: https://lnkd.in/gzw65bYm

Today, we announced alignment with the FDA on a plan to lift the clinical hold on our Phase 1/2 INGLAXA clinical trial for 4D-310 for Fabry disease #cardiomyopathy. In addition, we expect to share additional interim clinical data from INGLAXA for all 6 patients treated to date in Q1 2024. Read the full press release here: https://lnkd.in/gPdKNQpm 
#fabrydisease

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	460K -	954K 107.39%	1.74M 82.81%	1.79M 2.47%	4.76M 166.59%	3.32M 30.27%	3.52M 5.81%
accumulated other comprehensive income loss				-288.33M -	-423K 99.85%	-1.20M 182.74%	16K 101.34%
cash and cash equivalents	23.85M -	91.76M 284.74%	49.65M 45.89%	276.73M 457.33%	315.43M 13.99%	218.64M 30.68%	249.11M 13.93%
cash and short term investments	23.85M -	91.76M 284.74%	49.65M 45.89%	276.73M 457.33%	315.43M 13.99%	218.64M 30.68%	288.23M 31.83%
common stock	1K -	1K 0%	1K 0%	3K 200%	3K 0%	3K 0%	4K 33.33%
deferred revenue	4.38M -	4.91M 11.98%	5.86M 19.50%	6.59M 12.31%	2.60M 60.54%	884K 65.99%	273K 69.12%
deferred revenue non current	22.19M -	13.08M 41.07%	13.60M 4.03%	13.23M 2.77%	2.49M 81.17%	1.08M 56.80%	972K 9.67%
deferrred tax liabilities non current							-1 -
goodwill
goodwill and intangible assets
intangible assets
inventory					-8.50M -
long term debt					15.22M -	13.47M 11.49%	11.52M 14.46%
long term investments					67.65M -	4.91M 92.75%	10.95M 123.19%
net debt	-23.85M -	-91.76M 284.74%	-49.65M 45.89%	-276.73M 457.33%	-298.98M 8.04%	-202.52M 32.26%	-234.44M 15.76%
net receivables	321K -	1.12M 250.16%	978K 12.99%	1.49M 51.94%	47K 96.84%
other assets
other current assets	328K -	1.18M 260.67%		4.44M -	8.46M 90.28%	6.96M 17.73%	8.36M 20.11%
other current liabilities	1.01M -	2.10M 106.90%	5.35M 154.62%	8.37M 56.56%	7.74M 7.49%	8.87M 14.54%	12.01M 35.45%
other liabilities					526.10M -
other non current assets	105K -	429K 308.57%	677K 57.81%	602K 11.08%	-58.55M 9,825.42%	1.08M 101.84%	684K 36.67%
other non current liabilities	18.81M -	103.43M 449.73%	104.65M 1.18%	1.97M 98.11%	334K 83.08%	233K 30.24%	617K 164.81%
othertotal stockholders equity	884K -	2.44M 175.79%	6.05M 148.32%	392.06M 6,376.10%	420K 99.89%	1.19M 184.05%	723.14M 60,514.92%
preferred stock				288.33M -
property plant equipment net	2.72M -	2.47M 8.98%	5.05M 104.25%	5.07M 0.48%	28.95M 470.73%	35.35M 22.08%	31.66M 10.42%
retained earnings	-20.48M -	-30.03M 46.65%	-79.03M 163.19%	-135.68M 71.69%	-207.00M 52.56%	-314.49M 51.93%	-415.33M 32.06%
short term debt	51K -	93K 82.35%			1.23M -	2.65M 115.68%	3.15M 18.61%
short term investments					94.78M -	161.20M 70.09%	39.12M 75.73%
tax assets
tax payables	51K -	93K 82.35%
total assets	27.32M -	96.97M 254.94%	58.23M 39.95%	288.33M 395.12%	353.49M 22.60%	261.85M 25.92%	339.89M 29.81%
total current assets	24.50M -	94.07M 283.97%	52.51M 44.18%	282.66M 438.31%	315.43M 11.59%	220.51M 30.09%	296.59M 34.50%
total current liabilities	5.91M -	8.05M 36.32%	12.96M 60.85%	16.74M 29.25%	16.34M 2.42%	15.73M 3.72%	18.95M 20.47%
total debt					16.45M -	16.12M 1.97%	14.67M 9.01%
total investments					162.43M -	166.11M 2.27%	50.08M 69.85%
total liabilities	46.91M -	124.56M 165.52%	131.20M 5.34%	31.94M 75.65%	560.48M 1,654.58%	30.51M 94.56%	32.06M 5.09%
total liabilities and stockholders equity	27.32M -	96.97M 254.94%	58.23M 39.95%	288.33M 395.12%	353.49M 22.60%	-283.98M 180.34%	339.89M 219.69%
total non current assets	2.82M -	2.90M 2.84%	5.73M 97.38%	5.67M 0.89%	38.06M 570.63%	41.34M 8.61%	43.30M 4.76%
total non current liabilities	41.00M -	116.50M 184.14%	118.25M 1.50%	15.20M 87.15%	18.04M 18.70%	14.78M 18.09%	13.11M 11.28%
total stockholders equity	-19.59M -	-27.59M 40.82%	-72.97M 164.51%	256.39M 451.36%	-207.00M 180.74%	-314.49M 51.93%	307.83M 197.88%

COM:4DMOLECULARTHERAPEUTICS

4D Molecular Therapeutics Inc

Last Close

7.99

22/11 21:00

Market Cap

1.20B

Beta: -

Volume Today

2.60K

Avg: -

Preview